石四药集团（02005）今日盘中股价大跌6.67%，主要受到公司发布的2024年度业绩报告影响。该报告显示，公司业绩出现明显下滑，投资者信心受挫。
根据公司公告，截至2024年12月31日止年度，石四药集团实现收益57.73亿港元，同比减少10.67%；股东应占溢利10.61亿港元，同比减少19.53%。每股基本盈利为0.3582港元，公司拟派末期息每股0.095港元。这一业绩表现不及市场预期，导致投资者纷纷抛售该股。
从具体业务板块来看，公司大输液和安瓿水针产品业务保持相对稳定，但受政策性和市场性因素影响，基础输液市场需求乏力、价格下滑。原料药板块整体业务受国际市场和价格因素影响，销售额同比减少11.7%。尽管口服制剂业务板块产销规模有所提升，但未能抵消其他业务板块的下滑。分析人士认为，公司业绩下滑主要受到行业政策调整、市场竞争加剧以及原料药价格波动等多重因素影响，短期内业绩改善压力较大，这也是导致股价大幅下跌的主要原因。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.